Source:http://linkedlifedata.com/resource/pubmed/id/20739886
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2010-10-7
|
pubmed:abstractText |
Poly ADP-ribose polymerase inhibitors are a promising new area in cancer therapeutics. This review summarizes the current understanding of their mechanism of action, their state of clinical development, and possible mechanisms of resistance.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1531-703X
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
22
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
567-72
|
pubmed:meshHeading | |
pubmed:year |
2010
|
pubmed:articleTitle |
Poly ADP-ribose polymerase inhibitors: science and current clinical development.
|
pubmed:affiliation |
Women's Cancers Program, Medical Oncology Department, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|